Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Deffered Revenue (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $3.5 million as the latest value for Q2 2019.

  • Quarterly Non-Current Deffered Revenue rose 15.41% to $3.5 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Jun 2019, up 15.41% year-over-year, with the annual reading at $2.8 million for FY2018, 38.25% down from the prior year.
  • Non-Current Deffered Revenue for Q2 2019 was $3.5 million at Outlook Therapeutics, down from $4.1 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $12.7 million in Q3 2015, with the low at $2.8 million in Q3 2018.
  • Average Non-Current Deffered Revenue over 5 years is $4.8 million, with a median of $4.5 million recorded in 2017.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 59.51% in 2016, then grew 23.46% in 2019.
  • Over 5 years, Non-Current Deffered Revenue stood at $12.7 million in 2015, then crashed by 61.89% to $4.9 million in 2016, then dropped by 16.87% to $4.0 million in 2017, then grew by 16.58% to $4.7 million in 2018, then dropped by 24.84% to $3.5 million in 2019.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $3.5 million, $4.1 million, and $4.7 million for Q2 2019, Q1 2019, and Q4 2018 respectively.